Market Research

Psychedelic Invest is your source for the latest business and investing news about the burgeoning psychedelics industry.

Indiana Advances Psilocybin Research with New Funding Initiative

Apr 12 • 3 min read

Governor Eric Holcomb of Indiana has recently enacted a law that earmarks funds for clinical trials to explore the therapeutic effects of psilocybin. This development is part of a broader healthcare legislation that was modified to include provisions on psychedelic research, reflecting a growing interest in the medical potential of such substances. Origins and Goals…

Testing Psilocybin as a Treatment for Alcohol Use Disorder

Apr 12 • 2 min read

The University of Calgary’s Hotchkiss Brain Institute is poised to launch an innovative clinical trial investigating the use of psilocybin in treating alcohol use disorder (AUD). This trial, involving 128 participants diagnosed with AUD, integrates psychedelic therapy with structured talk-therapy sessions under the guidance of trained therapists. Initiating the Trial with Integrated Psychotherapy The trial…

All About the New Ketamine Trial at the University of Otago

Apr 12 • 3 min read

Depression remains one of the most challenging mental health conditions, affecting millions worldwide with varying degrees of severity. Traditional treatments like psychotherapy and antidepressants are effective for many, yet a subset of patients find these methods inadequate. This has led to a burgeoning interest in alternative treatments, among which ketamine therapy stands out due to…

Missouri Considers $10 Million from Opioid Settlements for Psilocybin Research

Apr 8 • 3 min read

Missouri’s legislative body, the House of Representatives, has recently endorsed a budget legislation earmarking $10 million of the state’s opioid settlement proceeds for research grants. However, these aren’t ordinary grants. Their purpose is to delve into the potential of psilocybin as a remedy for opioid use disorder, an issue that’s currently casting a shadow over…

Filament Health Nets $2.1M in Revenue in 2023

Apr 4 • 3 min read

Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) has recently shared its financial achievements for both the final quarter and the entire fiscal year ending December 31, 2023. This period has been notable for the biotech firm specializing in the development of natural psychedelic drugs, as it reported promising increases in revenue and a…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354